Examining the impact of TGF-ß activity on fibroblast infiltration and immune exclusion in MIBC.

S Shilpa Gupta (Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA) J Joep Jacobus de Jong (Erasmus MC Cancer Institute, Rotterdam, Netherlands) M Mohammed Alshalalfa J Jonathan Chou (Helen Diller Family Comprehensive Cancer Center, University of California) V Vadim S. Koshkin (Division of Hematology/Oncology, Department of Medicine University of California‐San Francisco San Francisco California USA) T Terence W. Friedlander D David Yoonsuk Oh (University of California, San Francisco, San Francisco, CA) S Sima P. Porten C Carissa E Chu (University of California San Francisco, San Francisco, CA) N Nataliya Mar (University of California Irvine, Irvine, CA) A Alexander Sasse A Anthony C. Wong (Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA) J James A. Proudfoot (Veracyte Inc, San Francisco, CA) E Elai Davicioni S Steven Neema Seyedin (University of California San Francisco, San Francisco, CA)

Abstract

851 Background: In urothelial cancer, transforming growth factor β (TGF-β) signaling in fibroblasts has been correlated with poor respose to immunotherapy (IO). We examined TGF- β activity scores in relation to the tumor micro-environment (TME) from muscle invasive bladder cancer (MIBC) patients and whether this correlated to response to neoadjuvant chemoIO utilized in the BLASST-01 trial. Methods: We assessed a prospective commercial cohort (PCC) consisting of the de-identified and anonymized transcriptome-wide expression profiles of N = 604 MIBC patients from the clinical use of the Decipher Bladder TURBT test that were available in the Decipher GRID registry (NCT02609269). Molecular subtypes were categorized by the consensus-MIBC subtyping model. Using GRID signatures, we applied the molecular signatures database hallmark gene set collection to quantify TGF-β hallmark signaling scores. Furthermore, we used TIDE (a computational framework on Tumor Immune Dysfunction and Exclusion) to quantify TME-related scores for cancer associated fibroblasts (CAF), immune exclusion, T regulatory cells and cytotoxic T-lymphocytes. The BLASST-01 trial investigated 4 cycles of neoadjuvant gemciatine, cisplatin, and nivoumab followed by radical cystectomy (RC). Pre-treament tumor specimens were examined for associations between molecular scores and pathological response (≤ypT1N0) at RC. Multivariable logistic regression analyses for pathologic response were adjusted for patient age and sex. Results: Intersection of TGF-β hallmark signaling scores with consensus molecular subtypes in the PCC cohort, we found elevated scores for the stroma-rich molecular subtype (p < 0.001). Furthermore, we found TGF-β scores had a significant positive correlation with CAFs (r = 0.41, p < 0.001), T regulatory cells (r = 0.33, p < 0.001) and immune exclusion (r = 0.47, p < 0.001), whereas we found a significant negative correlation between TGF-β hallmark signaling scores and infiltration of cytotoxic T-lymphocytes (r = -0.31, p < 0.001) and interferon γ (r = -0.35, p < 0.001). Additionally, TGF-β was highly correlated to hallmarks pathways related to epithelial-mesenchymal transition (EMT) (r = 0.36, p < 0.001) and angiogenesis (r > 0.31, p < 0.001) For BLASST-01, transcriptome data were available for 37/43 (86%); median age was 65 (IQR, 58-70), 41% were female, 89% were cT2N0 and 35% had pathological complete response. Higher scores for TGF-β signaling (OR 0.03, p < 0.005), immune exclusion (OR 0.37, p < 0.03) and CAFs (OR 0.41, p < 0.03) were associated with no pathological response, whereas cytotoxic T lymphocytes were significantly associated with pathological complete response (OR 7.04, p < 0.02). Conclusions: The present study demonstrates that molecular TGF-β activity scores are associated with fibroblast infiltration and immune exclusion, suggesting TGF-β attenuates response to neoadjuvant IO for MIBC.

Article Details

Volume / Issue Vol. 44, Issue 7_suppl
Published March 01, 2026
Pages 851-851
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (15)

S

Shilpa Gupta

Department of Hematology and Medical Oncology Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA

J

Joep Jacobus de Jong

Erasmus MC Cancer Institute, Rotterdam, Netherlands

M

Mohammed Alshalalfa

J

Jonathan Chou

Helen Diller Family Comprehensive Cancer Center, University of California

V

Vadim S. Koshkin

Division of Hematology/Oncology, Department of Medicine University of California‐San Francisco San Francisco California USA

T

Terence W. Friedlander

D

David Yoonsuk Oh

University of California, San Francisco, San Francisco, CA

S

Sima P. Porten

C

Carissa E Chu

University of California San Francisco, San Francisco, CA

N

Nataliya Mar

University of California Irvine, Irvine, CA

A

Alexander Sasse

A

Anthony C. Wong

Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA

J

James A. Proudfoot

Veracyte Inc, San Francisco, CA

E

Elai Davicioni

S

Steven Neema Seyedin

University of California San Francisco, San Francisco, CA